Its pretty simple Koo....you know what the primary endpoint of BETonMACE was I assume.  Going off memory it was to increase the time to first occurance of a Major Adverse Cardiac Event with patients suffering from Diabetes and low HDL.  So the BTD is for that same indication or patient population.....diabetic patients with low HDL at high risk of MACE.  

I might be slightly off on the finer points, but in broad strokes I think that's pretty close.